OCCUPATIONAL HEALTH AND SAFETY

Scholarship That Informs. Leadership That Protects.

A Public health doctor’s insight: Architecting Population-Level Safety in the Modern Workplace

Evansville, IN

|

Occupational Hazardous Metals and Cancer: How Workplace Exposure to Chromium, Nickel, Cadmium, and Arsenic Causes Aggressive Disease

By Dr. Srivathsan V. Raghavan, DrPH

Keywords: cancer‑causing metals, workplace, employers, workers, chromium, nickel, cadmium, arsenic, occupational cancer, workplace carcinogens, heavy metal exposure, epigenetic carcinogenesis, chromium nickel cadmium arsenic, industrial hygiene, employer safety responsibilities, public health agencies, DrPH leadership, cancer health inequities

cancer awareness campaign on blue surface
Photo by Anna Tarazevich on Pexels.com

Introduction

Work should never quietly shorten a person’s life, yet that is exactly what happens when employees are exposed to carcinogenic substances day after day. In many industries—metalworking, mining, construction, manufacturing, waste management, and even some service sectors—workers encounter hazardous metals and compounds that do not cause immediate illness but gradually reshape their biology in ways that can culminate in aggressive cancers. These exposures often occur in routine tasks: welding stainless steel, electroplating parts, handling contaminated dust, or working around poorly controlled emissions.

For a DrPH scholar and public health leaders more broadly, occupational cancer is not just a clinical or toxicological issue. It is a systems problem that spans regulation, organizational culture, labor rights, and health equity. Science has advanced rapidly in recent years, especially in understanding how metals such as arsenic, cadmium, chromium, and nickel influence cancer risk through epigenetic and epitranscriptomic mechanisms—changes in gene expression and RNA modification, rather than changes in the DNA sequence itself. These subtle alterations can switch off protective genes, amplify harmful pathways, and leave cells more vulnerable to malignant transformation.

Evidence from recent peer‑reviewed studies shows that occupational exposure to these metals is strongly linked to cancers of the lung, skin, bladder, liver, and other organs. Manić et al. (2022) describe how toxic metals interfere with epigenetic regulation, while Zhao et al. (2022) focus on chromium, nickel, and cadmium in occupational and environmental contexts. Wang and Yang (2023) delve into chromium’s effects on RNA‑level regulation, and Wu et al. (2026) quantify the global cancer burden attributable to occupational arsenic exposure, highlighting stark health inequalities. Together, these studies paint a clear picture: occupational cancer is both mechanistically understood and largely preventable, yet it remains under‑recognized and under‑addressed.

This blog article, written with a general audience in mind, synthesizes these findings in original language to explore how occupational hazards drive aggressive cancers, why these risks persist, and what employers, public health agencies, and medical professionals can do now to change the trajectory. The emphasis is on translating complex science into practical, actionable strategies that can be implemented in workplaces and health systems.

Analysis: How occupational hazards drive aggressive cancers

Epigenetic disruption as a central pathway in metal carcinogenesis

Many researchers preceded Manić et al. (2022) as early as the 1930s to 1960s, when carcinogenicity was given more importance under a broader field of toxicology; as a result, even subcutaneous intake of some of these metals, including vitallium, an alloy of cobalt, chromium, and molybdenum, is associated with certain cancers (Oppenheimer et al., 1956; Twort & Lyth, 1935; Twort & Lyth, 1935). Traditional views of carcinogens often focus on direct DNA damage—mutations caused by chemicals or radiation that lead to uncontrolled cell growth. While that remains important, recent research shows that many occupational metals exert their carcinogenic effects by altering the regulatory systems that control gene expression, rather than simply breaking DNA strands. Epigenetics refers to changes in how genes work without altering the underlying DNA code. Main examples of this include (Hanikoff & Greally, 2016):

  • DNA methylation and histone changes: Cells add tiny chemical tags to DNA or its scaffolding proteins to turn genes on or off.
  • Gene silencing and genomic imprinting: Genes can be completely switched off, sometimes depending entirely on which parent passed them down.
  • X chromosome inactivation and paternal chromosome silencing: Whole chromosomes from a parent can be completely shut down by the cell.
  • Paramutation and position-effect variegation: A gene’s activity can be permanently altered by interacting with another gene, or simply by its physical position inside the cell.

Manić et al. (2022) review how metals such as arsenic, cadmium, chromium, and nickel influence several key epigenetic processes:

  • DNA methylation: Metals can change the pattern of methyl groups attached to DNA, which in turn can silence genes that normally suppress tumors or support DNA repair. When these protective genes are turned off, cells become more susceptible to harmful accumulation of changes.
  • Histone modifications: DNA is wrapped around histone proteins. Metals can modify these proteins, altering how tightly DNA is packed and which genes are accessible for transcription. This can activate pathways that promote cell proliferation or stress survival, both of which can contribute to cancer development.
  • Non‑coding RNAs (including microRNAs): Metals can disrupt the production and function of small RNA molecules that fine‑tune gene expression. When these regulatory RNAs are altered, the balance between growth‑promoting and growth‑inhibiting signals can shift toward malignancy.

Many researchers preceded Manić et al. (2022) as early as the 1930s to 1960s, when carcinogenicity was given more importance under a broader field of toxicology; as a result, even subcutaneous intake of some of these metals, including vitallium, an alloy of cobalt, chromium, and molybdenum, is associated with certain cancers (Oppenheimer et al., 1956; Twort & Lyth, 1935; Twort & Lyth, 1935). These epigenetic changes are particularly concerning in occupational settings because they can persist long after exposure has ended. A worker who spent years in a high‑exposure job may carry epigenetic “signatures” of that exposure for decades, even if they later move into a safer environment. This delayed effect complicates surveillance and reinforces the importance of primary prevention—reducing or eliminating exposure before these changes occur.

Chromium, nickel, and cadmium: common industrial metals with uncommon consequences

Chromium, nickel, and cadmium are widely used in industrial processes and are frequently encountered in occupational environments. Workers in welding, electroplating, battery manufacturing, metal finishing, and certain chemical industries may be exposed to airborne particles, fumes, or contaminated surfaces containing these metals.

Zhao et al. (2022) synthesize current knowledge on how these metals contribute to carcinogenesis through epigenetic regulation. Their review highlights several recurring themes:

  • Oxidative stress and DNA damage: Hexavalent chromium (Cr(VI)) can generate reactive oxygen species that damage DNA and proteins. While some damage is repaired, repeated exposure can overwhelm repair systems, leading to mutations and chromosomal instability (Paithankar et al., 2021).
  • Interference with epigenetic enzymes: Nickel compounds can inhibit enzymes that normally remove methyl groups from histones, leading to persistent changes in chromatin structure and gene expression. This can lock cells into harmful expression patterns that favor cancer development (Martinez-Zamudio & Ha, 2011).
  • Disruption of DNA repair and inflammatory signaling: Cadmium has been shown to impair DNA repair pathways and promote chronic inflammation. Inflammation itself is a recognized driver of cancer, as it creates a microenvironment rich in growth factors and oxidative stress (Jin & Robertson, 2011).

Wang and Yang (2023) extend this picture by examining epitranscriptomic mechanisms—chemical modifications to RNA that influence how genetic information is translated into proteins. Chromium exposure can alter RNA methylation patterns, affecting the stability and translation efficiency of messenger RNAs. These changes can skew protein production toward pathways that support cell survival under stress, angiogenesis (the formation of new blood vessels), and other processes that facilitate tumor growth.

From a workplace perspective, these findings mean that even if exposures are below levels that cause acute toxicity, chronic low‑level exposure can still drive subtle but cumulative biological changes. Over time, these changes can manifest as lung cancers in welders, nasal and sinus cancers in metalworkers, or other malignancies in workers exposed to dusts and fumes.

Arsenic exposure and global cancer inequities

Arsenic occupies a unique place among occupational carcinogens because it is both an industrial hazard and a widespread environmental contaminant. Workers in mining, smelting, glass production, agriculture, semiconductor manufacturing, and water treatment may encounter arsenic in air, dust, or water. In many regions, arsenic‑contaminated groundwater also affects entire communities, blurring the line between occupational and environmental exposure.

Wu et al. (2026) conducted a large observational study spanning 32 years to estimate the cancer burden attributable to occupational arsenic exposure at global, regional, and national levels. Their analysis shows that arsenic exposure is associated with increased risks of cancers of the lung, skin, bladder, liver, and other organs. Importantly, they highlight that these burdens are not evenly distributed:

  • Regions with weaker regulatory frameworks and limited enforcement tend to have higher occupational arsenic exposure and higher associated cancer rates.
  • Workers in low‑income settings, informal sectors, and marginalized communities are more likely to be employed in high‑risk jobs with inadequate protective measures.
  • Projections to 2036 suggest that, without significant improvements in prevention and control, arsenic‑related cancer burdens will remain high or even increase in some regions.

This work underscores that occupational cancer is deeply intertwined with health equity. The workers most exposed to carcinogenic metals are often those with the least power to demand safer conditions, the least access to healthcare, and the least visibility in policy discussions. For DrPH scholars, this raises critical questions about how to design interventions that not only reduce exposure but also address structural inequities in labor markets, regulation, and health systems.

Why occupational cancer risks remain entrenched

Given the strength of the scientific evidence, it is reasonable to ask why occupational cancer risks persist. Several overlapping factors help explain this gap between knowledge and practice:

Regulatory limitations and uneven enforcement: Some countries lack stringent exposure limits for carcinogenic metals, or their standards are outdated relative to current science. Even where regulations exist, enforcement may be inconsistent due to limited resources, political pressures, or competing economic priorities. Small and medium‑sized enterprises, in particular, may operate with minimal oversight.

Limited awareness among employers and workers: Occupational cancer develops slowly, often over decades. Because the effects are delayed and non‑specific, workers and employers may not connect current exposures with future disease. Safety programs may focus on acute injuries and limited exposure to workplace hazards, while chronic carcinogenic risks receive less attention.

Insufficient industrial hygiene infrastructure: Effective control of metal exposures requires engineering controls (such as local exhaust ventilation), exposure monitoring, and trained safety personnel. Many workplaces—especially in low‑resource settings—lack these systems. Without reliable data on exposure levels, it is difficult to prioritize interventions or evaluate their impact.

Economic pressures and perceived costs: Replacing hazardous materials, upgrading equipment, or installing ventilation systems can be expensive. Employers facing tight margins may delay investments in safety, especially if they do not perceive immediate benefits or if enforcement is weak.

Structural inequities and vulnerable workers: Migrant workers, racial and ethnic minorities, and those in precarious employment are more likely to work in high‑exposure jobs and less likely to have access to health insurance, regular medical care, or union representation. These inequities amplify the health impact of occupational carcinogens and complicate efforts to implement comprehensive prevention strategies.

The strategic role of public health leadership and DrPH scholars

Addressing occupational cancer requires more than technical fixes; it demands leadership that can integrate science, policy, organizational change, and community engagement. DrPH scholars are uniquely positioned to play this role because their training spans epidemiology, health policy, management, and implementation science.

Key contributions include:

  • Translating evidence into policy: Synthesizing research on epigenetic and epitranscriptomic mechanisms into clear, actionable recommendations for exposure limits, surveillance systems, and regulatory frameworks.
  • Designing and evaluating interventions: Developing workplace programs that combine engineering controls, administrative policies, and worker education, then rigorously assessing their effectiveness.
  • Advocating for vulnerable populations: Highlighting the disproportionate burden of occupational cancer among low‑income and marginalized workers, and pushing for policies that address these inequities.
  • Building cross‑sector partnerships: Connecting employers, labor organizations, public health agencies, and healthcare providers to create integrated prevention and early detection strategies.
  • Communicating risk in accessible ways: Explaining complex mechanisms—such as epigenetic changes—in language that resonates with workers, managers, and policymakers, thereby increasing buy-in for preventive measures.

In short, public health leadership can help shift occupational cancer from a “silent” problem to a visible priority, backed by both scientific evidence and moral urgency.

Summary

Occupational exposure to carcinogenic metals such as arsenic, cadmium, chromium, and nickel remains a significant driver of aggressive cancers among workers worldwide. Recent research has moved beyond a narrow focus on direct DNA damage to reveal how these metals reshape the regulatory systems that control gene and RNA expression. Manić et al. (2022) describe how metals alter DNA methylation, histone modifications, and non‑coding RNA networks, undermining tumor‑suppressive mechanisms and DNA repair. Zhao et al. (2022) show that chromium, nickel, and cadmium contribute to cancer through oxidative stress, interference with epigenetic enzymes, and disruption of inflammatory and repair pathways. Wang and Yang (2023) highlight chromium’s impact on RNA‑level regulation, adding another layer to our understanding of how chronic exposure can drive malignant transformation. Wu et al. (2026) quantify the global cancer burden attributable to occupational arsenic exposure and reveal stark health inequalities, with vulnerable workers bearing the greatest risks.

Despite this robust evidence, occupational cancer risks persist due to regulatory gaps, limited awareness, inadequate industrial hygiene infrastructure, economic pressures, and structural inequities. For DrPH scholars and public health leaders, the challenge is to convert mechanistic insight into practical, equitable prevention strategies. This means strengthening regulations, improving workplace controls, enhancing surveillance, and ensuring that the voices of high‑risk workers are heard in policy debates. Ultimately, occupational cancer is largely preventable; the question is whether employers, agencies, and health systems will act decisively enough to realize that potential.

Advertisements

Call-to-Action

For employers

  • Prioritize substitution and elimination: Whenever feasible, replace carcinogenic metals or processes with safer alternatives. Conduct systematic hazard assessments to identify opportunities for substitution.
  • Invest in engineering controls: Install and maintain local exhaust ventilation, enclosed systems, and effective filtration to reduce airborne metal concentrations. Ensure that equipment is regularly inspected and upgraded as needed.
  • Implement exposure monitoring: Conduct routine measurements of airborne metals and surface contamination. Share results transparently with workers and use data to guide improvements.
  • Strengthen training and communication: Provide clear, practical training on carcinogenic risks, safe work practices, and proper use of personal protective equipment (PPE). Reinforce messages regularly rather than treating training as a one‑time event.
  • Ensure access to high‑quality PPE: Supply appropriate respirators, gloves, protective clothing, and eye protection, and enforce their use. Fit‑testing and maintenance should be standard practice.
  • Establish medical surveillance programs: Partner with occupational health providers to offer regular health assessments for workers in high‑exposure roles, including targeted screening for early signs of exposure‑related disease.

For public health agencies

  • Update and enforce standards: Review exposure limits for carcinogenic metals in light of current epigenetic and epitranscriptomic evidence. Strengthen enforcement mechanisms, particularly in high‑risk industries and small enterprises.
  • Develop robust surveillance systems: Create registries that track occupational exposures and cancer outcomes, enabling early detection of trends and evaluation of interventions.
  • Support research and translation: Fund studies that explore emerging carcinogens, combined exposures, and effective control strategies, and ensure that findings are translated into practical guidance for workplaces.
  • Engage communities and workers: Design outreach programs that inform workers, unions, and community organizations about occupational cancer risks and rights to a safe workplace.
  • Address health inequities: Prioritize interventions in sectors and regions where vulnerable workers face the highest exposures and the least protection. Integrate occupational health into broader health equity agendas.
  • Collaborate across sectors: Work with labor ministries, environmental agencies, and industry groups to align policies and incentives around prevention, rather than relying on fragmented efforts.

For medical personnel

  • Take detailed occupational histories: Incorporate questions about current and past jobs, exposures, and use of protective equipment into routine clinical assessments, especially for patients with respiratory, dermatologic, or hematologic symptoms.
  • Recognize patterns of exposure‑related disease: Stay alert to clusters of cancers or pre‑cancerous conditions among workers in specific industries, and communicate concerns to public health authorities when patterns emerge.
  • Provide targeted screening and counseling: Offer appropriate screening for high‑risk workers and counsel them on ways to reduce exposure, including advocating for safer conditions at their workplaces.
  • Collaborate with occupational health and public health: Participate in multidisciplinary teams that link clinical care with workplace interventions and policy advocacy.
  • Educate patients and employers: Use clinical encounters as opportunities to raise awareness about occupational carcinogens and the importance of prevention, both at the individual and organizational levels.

Dr. Srivathsan Raghavan is a researcher and practitioner dedicated to solving systemic vulnerabilities within industrial infrastructure. As a Doctor of Public Health, he emphasizes Occupational Health and Safety. He bridges translational science and large-scale corporate execution. Dr. Raghavan integrates rigorous academic theory with real-world operations management to analyze and mitigate environmental health threats. His writing provides evidence-based insights into HAZMAT RMP (Hazardous Materials Responsible Management Person) compliance, offering clinical, scientific, and administrative peers a clear view of how operational design directly affects workforce longevity, population health outcomes, and institutional risk.

References:

Henikoff, S., & Greally, J. M. (2016). Epigenetics, cellular memory and gene regulation. Current biology, 26(14), R644-R648.

Jin, B., Li, Y., & Robertson, K. D. (2011). DNA methylation: superior or subordinate in the epigenetic hierarchy?. Genes & Cancer, 2(6), 607–617.

Manić, L., Wallace, D., Onganer, P. U., Taalab, Y. M., Farooqi, A. A., Antonijević, B., & Buha Djordjevic, A. (2022). Epigenetic mechanisms in metal carcinogenesis. Toxicology Reports, 9, 778–787. https://doi.org/10.1016/j.toxrep.2022.03.037.

Martinez-Zamudio, R., & Ha, H. C. (2011). Environmental epigenetics in metal exposure. Epigenetics, 6(7), 820–827.

Oppenheimer, B. S., Oppenheimer, E. T., Danishefsky, I., Stout, A. P., & Willhite, M. (1956). Carcinogenic effect of metals in rodents. Cancer Research, 16(5), 439–441.

Paithankar, J. G., Saini, S., Dwivedi, S., Sharma, A., & Chowdhuri, D. K. (2021). Heavy metal associated health hazards: An interplay of oxidative stress and signal transduction. Chemosphere, 262, 128350. https://doi.org/10.1016/j.chemosphere.2020.128350.

Twort, C. C., & Lyth, R. (1935). A new method for measuring carcinogenicity. Epidemiology & Infection, 35(1), 125–129.

Twort, C. C., & Lyth, R. (1935). The violence of reaction of the animal in relation to the etiology of cancer and inflammation. Epidemiology & Infection, 35(3), 404–411.

Zhao, L., Islam, R., Wang, Y., Zhang, X., & Liu, L. Z. (2022). Epigenetic regulation in chromium-, nickel- and cadmium-induced carcinogenesis. Cancers, 14(23), 5768. https://doi.org/10.3390/cancers14235768.

Wang, Z., & Yang, C. (2023). Epigenetic and epitranscriptomic mechanisms of chromium carcinogenesis. Advances in Pharmacology (San Diego, Calif.), 96, 241–265. https://doi.org/10.1016/bs.apha.2022.07.002.

Wu, D., Li, X., Luo, M., Gao, N., Wang, X., Li, A., Mo, Z., Gazala, Z., Yan, S., Wu, L., Zhang, R., & Pei, J. (2026). Cancer burden and health inequalities attributable to occupational arsenic exposure: A 32-year global, regional, and national observational study with projections to 2036. Medicine, 105(31), e49979. https://doi.org/10.1097/MD.0000000000049979.